Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Predictive Toxicology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1406860

A Web-Based Scoping Review Assessing the Influence of Smoking and Smoking Cessation on Antidiabetic Drug Metabolism: Implications for Medication Efficacy

Provisionally accepted
Carlo Maria Bellanca Carlo Maria Bellanca 1Egle Augello Egle Augello 1Giulia Di Benedetto Giulia Di Benedetto 1Chiara Burgaletto Chiara Burgaletto 1Anna Flavia Cantone Anna Flavia Cantone 1Giuseppina Cantarella Giuseppina Cantarella 1,2*Renato Bernardini Renato Bernardini 1Riccardo Polosa Riccardo Polosa 3DiaSmokeFree Working Group DiaSmokeFree Working Group 4
  • 1 Department of Biomedical and Biotecnological Sciences, Catania, Sicily, Italy
  • 2 University of Catania, Catania, Italy
  • 3 Department of Clinical and Experimental Medicine, University of Catania, Catania, Sicily, Italy
  • 4 DiaSmokeFree working group, Catania, Italy

The final, formatted version of the article will be published soon.

    Currently 1.3 billion individuals globally engage in smoking, leading to significant morbidity and mortality, particularly among diabetic patients. There is urgent need for a better understanding of how smoking influences antidiabetic treatment efficacy. The review underscores the role of cigarette smoke, particularly polycyclic aromatic hydrocarbons (PAHs), in modulating the metabolic pathways of antidiabetic drugs, primarily through the induction of cytochrome P450 (CYP450) enzymes and uridine diphosphate (UDP)-glucuronosyltransferases (UGTs), thus impacting drug pharmacokinetics and therapeutic outcomes. Furthermore, the review addresses the relatively uncharted territory of how smoking cessation influences diabetes treatment, noting that cessation can lead to significant changes in drug metabolism, necessitating dosage adjustments. Special attention is given to the interaction between smoking cessation aids and antidiabetic medications, a critical area for patient safety and effective diabetes management. This scoping review aims to provide healthcare professionals with the knowledge to better support diabetic patients who smoke or are attempting to quit, ensuring tailored and effective treatment strategies. It also identifies gaps in current research, advocating for more studies to fill these voids, thereby enhancing patient care and treatment outcomes for this at-risk population.

    Keywords: adverse drug reactions, cytochrome P450, Diabetes Mellitus, drug-drug interactions, drug metabolism, Smoking Cessation

    Received: 25 Mar 2024; Accepted: 20 May 2024.

    Copyright: © 2024 Bellanca, Augello, Di Benedetto, Burgaletto, Cantone, Cantarella, Bernardini, Polosa and Working Group. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Giuseppina Cantarella, University of Catania, Catania, Italy

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.